Journal Article (Review Article) DZNE-2020-06956

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Posterior reversible encephalopathy syndrome.

 ;  ;

2019
Ovid [S.l.]

Current opinion in neurology 32(1), 25-35 () [10.1097/WCO.0000000000000640]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological syndrome characterized by acute cerebral endotheliopathy with consecutive disruption of the blood-brain barrier and vasogenic edema. Since its first description in 1996, PRES is increasingly recognized. However, many aspects of this syndrome with its wide spectrum of clinical and radiological features are still incompletely understood. In this review, possible pathophysiological mechanisms, approaches to diagnosis, recent study results on outcome, and future directions of research are described.Clinical manifestations of PRES include seizures, headache, visual disturbances, altered mental state, and more rarely hemiparesis or aphasia. Vasogenic edema predominantly occurs in the parieto-occipital region, but lesions affecting formerly called 'atypical' regions such as frontal lobe, cerebellum, or basal ganglia are common. If treated early and adequately, that is by removal of the underlying cause, PRES has a favorable prognosis, but neurological residual symptoms and even mortality can occur, particularly in patients with complications such as intracranial hemorrhage.In summary, validated diagnostic criteria and algorithms are warranted to standardize the diagnosis of PRES. This is essential for further research and future prospective studies that should investigate risk factors for unfavorable outcome and identify the roles of imaging features, clinical symptoms, and other biomarkers in predicting outcome.

Keyword(s): Blood-Brain Barrier: diagnostic imaging (MeSH) ; Humans (MeSH) ; Magnetic Resonance Imaging: methods (MeSH) ; Posterior Leukoencephalopathy Syndrome: diagnosis (MeSH) ; Prognosis (MeSH) ; Risk Factors (MeSH)

Classification:

Contributing Institute(s):
  1. Coordinator of Clinical Research (AG Endres)
Research Program(s):
  1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2019
Database coverage:
Medline ; Allianz-Lizenz ; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; IF >= 5 ; JCR ; SCOPUS ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > B DZNE > B DZNE-AG Endres
Public records
Publications Database

 Record created 2020-02-18, last modified 2024-03-21



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)